PolyPid Ltd. (PYPD)
PolyPid Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Petah Tikva, HM, IL. The stock last traded at $5.22, down 2.61% on the session, giving a market capitalisation of $99.6M. On trailing twelve-month figures it carries a trailing P/E of -3.53, a net margin of 0.0%. Its beta of 1.42 implies it has historically moved more than the broad market.
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
PolyPid Ltd. is most often compared with the following Healthcare names: